Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 11/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 7/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.36 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL626795 | 0.89 | PIK3CA (0.41) | PIK3CACYP3A4FYNPIK3CDPIK3CB | |
| SCHEMBL627323 | 0.88 | FYN (0.48) | PIK3CACYP3A4FYNPIK3CDPIK3CB | |
| SCHEMBL627321 | 0.88 | FYN (0.48) | PIK3CACYP3A4FYNPIK3CDPIK3CB | |
| SCHEMBL627468 | 0.87 | HASPIN (0.43) | PIK3CACYP3A4FYNPIK3CDPIK3CB | |
| SCHEMBL627466 | 0.87 | HASPIN (0.43) | PIK3CACYP3A4FYNPIK3CDPIK3CB | |
| SCHEMBL626188 | 0.84 | MAP3K12 (0.41) | PIK3CAMAP3K12 | |
| SCHEMBL628259 | 0.81 | DPP4 (0.38) | PIK3CAFYNPIK3CDPIK3CBPIK3CG | |
| SCHEMBL628257 | 0.81 | DPP4 (0.38) | PIK3CAFYNPIK3CDPIK3CBPIK3CG | |
| SCHEMBL627322 | 0.76 | FYN (0.48) | PIK3CACYP3A4FYNPIK3CDPIK3CB | |
| SCHEMBL627398 | 0.75 | PIK3CA (0.53) | PIK3CAFYNHASPIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024130027-A2 | PROTAC DEGRADATION OF FACTORS PAX3 AND FOXO1 | THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (US) | 2024-06-20 | — | — | WO | disclosed |
| EP-4370126-A1 | SMALL MOLECULE CYCLIN DEPENDENT KINASE 4/6 (CDK4/6) AND IKZF2 (HELIOS) DEGRADERS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-4367115-A1 | DEGRADERS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-4353747-A2 | COMBINATION OF ZANUBRUTINIB WITH AN ANTI-CD20 OR AN ANTI-PD-1 ANTIBODY FOR USE IN TREATING CANCER | BeiGene Switzerland GmbH (CH) | 2024-04-17 | — | — | EP | disclosed |
| EP-3500299-B1 | COMBINATION OF ZANUBRUTINIB WITH AN ANTI-CD20 OR AN ANTI-PD-1 ANTIBODY FOR USE IN TREATING CANCER | BEIGENE SWITZERLAND GMBH (CH) | 2023-12-13 | — | — | EP | disclosed |
| US-20230364096-A1 | USE OF A COMBINATION COMPRISING A BTK INHIBITOR FOR TREATING CANCERS | BEONE MEDICINES I GMBH (CH) | 2023-11-16 | — | — | US | disclosed |
| WO-2023133260-A2 | CHEMICAL TARGETING SWI/SNF RELATED, MATRIX ASSOCIATED, ACTIN DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY A, MEMBER 4 (SMARCA4) AND USE IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| EP-4168003-A2 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-4168441-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | Dana-Farber Cancer Institute, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-4153175-A1 | PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2023-03-29 | — | — | EP | disclosed |
| EP-2032583-A1 | NEW CHEMICAL COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2009-03-11 | — | — | EP | disclosed |
| EP-2024370-A1 | SPIRO- (THO) BENZOPYRAN-2, 4' -PIPERIDINE-AND CYCLOHEXANE DERIVATIVES AS INHIBITORS OF SPECIFIC CELL CYCLE ENZYMES | Boehringer Ingelheim International GmbH (DE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2009003998-A2 | ANTIPROLIFERATIVE COMPOUNDS BASED ON 5-MEMBERED HETEROCYCLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009003999-A2 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009000832-A2 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-31 | — | — | WO | disclosed |
| WO-2008152013-A1 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008152014-A2 | 3-HETROCYCLYLIDENE-INDOLINONE DERIVATIVES AS INHIBITORS OF SPECIFIC CELL CYCLE KINASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008107444-A1 | 9H- PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-12 | — | — | WO | disclosed |
| WO-2007144370-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007128782-A1 | SPIRO- (THO) BENZOPYRAN-2, 4' -PIPERIDINE-AND CYCLOHEXANE DERIVATIVES AS INHIBITORS OF SPECIFIC CELL CYCLE ENZYMES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364096-A1 | USE OF A COMBINATION COMPRISING A BTK INHIBITOR FOR TREATING CANCERS | BTK, LCK, LYN | PIK3CA 78/4885CYP3A4 4413/4885FYN 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.